Video
Nasal spray claims to improve treatment-resistant depressionAntidepressant for treatment-resistant depression -
Studies also reported dropout rates for any reason as a measure of treatment harm. One small, low-quality study demonstrated that switching from fluoxetine to mianserin a tetracyclic antidepressant not available in the United States did not improve depression scores, response rates, or remission rates.
Two European studies evaluated the benefit of augmenting fluoxetine therapy with another antidepressant. Augmentation with mianserin at a daily dosage of 60 mg increased both response and remission rates, without increasing drop-out rates.
Augmentation with mirtazapine Remeron , 30 mg daily, failed to improve depression symptoms, response rates, or remission rates after 12, 24, or 52 weeks. One study in which fluoxetine or citalopram Celexa was augmented with buspirone Buspar , 10 to 30 mg twice daily, showed no improvement in depression scores or response rates compared with placebo.
Augmentation with atypical antipsychotics had more evidence of benefit. Although use of quetiapine did not affect drop-out rates overall, dosages of mg daily increased dropouts, whereas lower dosages did not. Augmenting an SSRI or SNRI with cariprazine, 1 to 4. Guidelines from the Institute for Clinical Systems Improvement ICSI and the National Institute for Health and Care Excellence NICE recommend augmenting antidepressant therapy to manage treatment-resistant depression.
ICSI suggests augmentation with bupropion, buspirone, mirtazapine, thyroxine, stimulants, lithium, or atypical antipsychotics. Editor's Note: The NNTs, NNHs, and CIs reported in this Cochrane for Clinicians were calculated by the authors based on raw data provided in the original Cochrane review.
Arnold is a contributing editor for AFP. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of the Air Force, Uniformed Services University of the Health Sciences, Department of Defense, or the U.
Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. Mrazek DA, Hornberger JC, Altar CA, et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: — Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition.
Am J Psychiatry ; supplement American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, aspx Accessed on April 17, Cleare A, Pariante CM, Young AH, et al.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the British Association for Psychopharmacology guidelines.
J Psychopharmacol ; McIntyre RS, Suppes T, Tandon R, Ostacher M. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. J Clin Psychiatry ; National Institute for Health and Care Excellence.
Depression in adults: treatment and management. NICE guideline ng June 29, The Treatment and Management of Depression in Adults updated edition. National Clinical Practice Guideline 90, Hansen RA, Dusetzina SB, Ellis AR, et al. Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies.
Gen Hosp Psychiatry ; Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Gaynes BN, Warden D, Trivedi MH, et al.
Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv ; Mohamed S, Johnson GR, Chen P, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
Zisook S, Johnson GR, Tal I, et al. General Predictors and Moderators of Depression Remission: A VAST-D Report. Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies.
Prim Care Companion J Clin Psychiatry ; Fava M. Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes VAST-D Study. Han C, Wang SM, Kwak KP, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
J Psychiatr Res ; Lenze EJ, Mulsant BH, Roose SP, et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. Fang Y, Yuan C, Xu Y, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
J Clin Psychopharmacol ; Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Santaguida P, MacQueen G, Keshavarz H, et al. Treatment for Depression After Unsatisfactory Response to SSRIs. Comparative Effectiveness Review No. Prepared by McMaster University Evidence-based Practice Center under Contract No. HHSA I. AHRQ Publication No. Agency for Healthcare Research and Quality.
Treatment for Depression after Unsatisfactory Response to SSRIs. April, Gaynes BN, Lux L, Lloyd S, et al. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Gaynes BN, Dusetzina SB, Ellis AR, et al. Navarro V, Boulahfa I, Obach A, et al.
Switching to Imipramine Versus Add-on Mirtazapine in Venlafaxine-Resistant Major Depression: A Week Randomized Open Study. Baethge C. Guideline advice on second-step antidepressant treatment: The evidence for IDAS in MIDAS. Bipolar Disord ; Strawbridge R, Carter B, Marwood L, et al. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis.
Dunlop BW, LoParo D, Kinkead B, et al. Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
Greer TL, Trombello JM, Rethorst CD, et al. Depress Anxiety ; Danielsson L, Papoulias I, Petersson EL, et al. Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study.
Preskorn SH. Treatment options for the patient who does not respond well to initial antidepressant therapy. J Psychiatr Pract ; Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.
J Clin Psychiatry ; 70 Suppl Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs ; Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression.
A meta-analysis. Arch Gen Psychiatry ; McLachlan G. Treatment resistant depression: what are the options? BMJ ; k Bauer M, Dell'osso L, Kasper S, et al. Extended-release quetiapine fumarate quetiapine XR monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
J Clin Psychiatry ; e Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. Papadimitropoulou K, Vossen C, Karabis A, et al.
Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin ; Yan Y, Yang X, Wang M, et al. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.
Psychol Med ; Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol ; Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry ; Jawad MY, Alnefeesi Y, Lui LMW, et al. Olanzapine and samidorphan combination treatment: A systematic review.
Wang HR, Woo YS, Ahn HS, et al. Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance?
A Meta-Analysis of Randomized Controlled Trials. Int J Neuropsychopharmacol ; Trivedi MH, Thase ME, Osuntokun O, et al. Tohen M, Case M, Trivedi MH, et al.
Cheon EJ, Lee KH, Park YW, et al. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
Kishimoto T, Hagi K, Kurokawa S, et al. Zall H, Therman PG, Myers JM. Lithium carbonate: a clinical study. Nelson JC, Baumann P, Delucchi K, et al.
A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Henssler J, Alexander D, Schwarzer G, et al. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis.
Lithium Augmentation Versus Citalopram Combination in Imipramine-Resistant Major Depression: A Week Randomized Open-Label Study. Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA.
Enhancement of imipramine antidepressant activity by thyroid hormone. Nierenberg AA, Fava M, Trivedi MH, et al. Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
McPherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand ; Trivedi RB, Nieuwsma JA, Williams JW Jr. Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review.
J Gen Intern Med ; Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression.
World Psychiatry ; Parikh SV, Quilty LC, Ravitz P, et al. Canadian Network for Mood and Anxiety Treatments CANMAT Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2.
Psychological Treatments. Ijaz S, Davies P, Williams CJ, et al. Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev ; 5:CD van Bronswijk S, Moopen N, Beijers L, et al.
Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial.
Nakagawa A, Mitsuda D, Sado M, et al. Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial. Murray G, Michalak EE, Axler A, et al. Relief of chronic or resistant depression Re-ChORD : a pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression.
Fonagy P, Rost F, Carlyle JA, et al. Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study TADS.
Town JM, Abbass A, Stride C, Bernier D. A randomised controlled trial of Intensive Short-Term Dynamic Psychotherapy for treatment resistant depression: the Halifax Depression Study. Liu B, Zhang Y, Zhang L, Li L. Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study.
BMC Psychiatry ; Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments CANMAT Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Papakostas GI, Fava M, Thase ME.
Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry ; Ruhé HG, Huyser J, Swinkels JA, Schene AH.
Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. Rush AJ, Trivedi MH, Wisniewski SR, et al.
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U. Poison Control Centers, Köhler-Forsberg O, Larsen ER, Buttenschøn HN, et al.
Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.
Fava M, Rush AJ, Wisniewski SR, et al. Thase ME. The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry ; 73 Suppl Fekadu A, Rane LJ, Wooderson SC, et al. Prediction of longer-term outcome of treatment-resistant depression in tertiary care.
Suchting R, Tirumalajaru V, Gareeb R, et al. Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis.
Schosser A, Serretti A, Souery D, et al. European Group for the Study of Resistant Depression GSRD --where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol ; Nakagome K, Yokoi Y, Nakagawa A, et al. Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial.
Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.
Iosifescu DV. Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress.
Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. Bschor T, Kern H, Henssler J, Baethge C. Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis.
J Clin Psychiatry Thase ME, Friedman ES, Biggs MM, et al. Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: medication nefazodone or psychotherapy CBASP is effective when the other is not.
Mutz J, Vipulananthan V, Carter B, et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis.
BMJ ; l Sanacora G, Frye MA, McDonald W, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. Andrade C. Ketamine for Depression, 2: Diagnostic and Contextual Indications. Singh I, Morgan C, Curran V, et al. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.
Lancet Psychiatry ; Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments CANMAT Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété Canmat Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.
Ketamine for Depression, 3: Does Chirality Matter? Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Anand A, Mathew SJ, Sanacora G, et al.
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Espinoza RT, Kellner CH.
Electroconvulsive Therapy. Reif A, Bitter I, Buyze J, et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. Rhee TG, Shim SR, Forester BP, et al.
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis. Menon V, Varadharajan N, Faheem A, Andrade C.
Ketamine vs Electroconvulsive Therapy for Major Depressive Episode: A Systematic Review and Meta-analysis. Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Malhi GS, Byrow Y, Cassidy F, et al.
Ketamine: stimulating antidepressant treatment? BJPsych Open ; 2:e5. Freedman R. Ketamine and ECT in Depression - Risks and Rewards. Kellner CH, Greenberg RM, Murrough JW, et al. ECT in treatment-resistant depression. Allan C, Kalu UG, Sexton CE, Ebmeier KP.
Transcranial stimulation in depression. Lisanby SH. Electroconvulsive therapy for depression. Patel M, Patel S, Hardy DW, et al. Should electroconvulsive therapy be an early consideration for suicidal patients?
J ECT ; Brådvik L, Berglund M. Long-term treatment and suicidal behavior in severe depression: ECT and antidepressant pharmacotherapy may have different effects on the occurrence and seriousness of suicide attempts.
Kellner CH, Fink M, Knapp R, et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review.
FDA Executive Summary: Prepared for the January , meeting of the Neurological Devices Panel. Meeting to Discuss the Classification of Electroconvulsive Therapy Devices ECT. pdf Accessed on May 25, Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression.
UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Folkerts HW, Michael N, Tölle R, et al. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression -- a randomized study.
Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation rTMS? A meta-analysis of the efficacy of rTMS in psychiatric disorders.
Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation rTMS versus electroconvulsive therapy ECT for major depression: a systematic review and meta-analysis of randomized trials. Health Quality Ontario. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ont Health Technol Assess Ser ; Ren J, Li H, Palaniyappan L, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry ; Hansen PE, Ravnkilde B, Videbech P, et al.
Psychological counseling psychotherapy by a psychiatrist, psychologist or other mental health professional can be very effective. For many people, psychotherapy combined with medication works best.
It can help identify underlying concerns that may be adding to your depression. In working with your therapist, you can also learn specific behaviors and strategies to overcome your depression. For example, psychotherapy can help you:.
If counseling doesn't seem helpful, talk to your psychotherapist about trying a different approach. Or consider seeing someone else. As with medications, it may take several tries to find a treatment that works.
Psychotherapy for depression may include:. If medications and psychotherapy aren't working, you may want to talk to a psychiatrist about additional treatment options:. Don't settle for a treatment that's partially effective at relieving your depression or one that works but causes intolerable side effects.
Work with your doctor or other mental health professional to find the best treatment possible, even though it may take time and effort to try new approaches. There is a problem with information submitted for this request.
Sign up for free and stay up to date on research advancements, health tips, current health topics, and expertise on managing health. Click here for an email preview.
Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you.
If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices.
You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail. You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
This content does not have an English version. This content does not have an Arabic version. Appointments at Mayo Clinic Mayo Clinic offers appointments in Arizona, Florida and Minnesota and at Mayo Clinic Health System locations.
Request Appointment. Treatment-resistant depression. Products and services. Treatment-resistant depression Sometimes depression doesn't get better, even with treatment. Explore what you can do about it. By Mayo Clinic Staff. Related video Psychiatry and Psychology: Mayo Clinic Depression Center.
Thank you for subscribing! Sorry something went wrong with your subscription Please, try again in a couple of minutes Retry. Show references Thase M, et al. Unipolar depression in adults: Treatment of resistant depression. Accessed March 1, ECT, TMS and other brain stimulation therapies.
National Alliance on Mental Illness. Sanacora G, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. Lebow J. Overview of psychotherapies. Ionescu DF, et al. Pharmacological approaches to the challenge of treatment-resistant depression.
Dialogues in Clinical Neuroscience. Bewernick B, et al. Update on neuromodulation for treatment-resistant depression. De Sousa RT, et al. Challenging treatment-resistant major depressive disorder: A roadmap for improved therapeutics.
Current Neuropharmacology. Thase M, et al.
Treatment-esistant a treatment-resixtant with major depressive Glycogen storage for endurance athletes MDD Antidepressant for treatment-resistant depression not responded to at least foor types of medication, they have Antiddepressant depression. Antidepressant for treatment-resistant depression means that they have not experienced adequate relief Fat burn arms their symptoms after trying two different treatment methods. Although treatment-resistant depression can be difficult to manage, doctors have a variety of interventions to treat it. One choice involves changing from a first-line medication to an older antidepressant drug. They may also recommend psychotherapy, brain stimulation, or new drugs. According to a study published in the Journal of Clinical Psychiatry, MDD, also called clinical depression, can cause :. Feeling sad or hopeless from time to time is a Depresdion and cor part of life. Trewtment-resistant happens to everyone. For people with depression Resveratrol side effects, these feelings can become intense and long-lasting. This can lead to problems at work, home, or school. Depression is usually treated with a combination of antidepressant medication and certain types of therapy, including psychotherapy. For some, antidepressants provide enough relief on their own. In addition, 30—40 percent notice only a partial improvement in their symptoms.
0 thoughts on “Antidepressant for treatment-resistant depression”